Merus BV (MRUS)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Sven A. Lundberg
Employees:
37
YALELAAN 62, 3584 CM UTRECHT, NETHERLANDS 3584 CM
31 030 253 8800

Merus N.V. engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials. The company is also developing MCLA-158,158,145, and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma.

Data derived from most recent annual or quarterly report
Market Cap 1.193 Billion Shares Outstanding49.859 Million Avg 30-day Volume 400.421 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.43
Price to Revenue27.8112 Debt to Equity0.0 EBITDA-187.277 Million
Price to Book Value3.229 Operating Margin-356.15009999999995 Enterprise Value824.42 Million
Current Ratio6.294 EPS Growth-1.625 Quick Ratio6.095
1 Yr BETA 0.9757 52-week High/Low 27.7 / 12.44 Profit Margin-386.9992
Operating Cash Flow Growth9.6791 Free Cash Flow to Firm (FCFF) TTM -135.569 Million Free Cash Flow to Equity (FCFE) TTM-119.932 Million
Altman Z-Score5.4262
Earnings Report2024-02-27
View SEC Filings from MRUS instead.

View recent insider trading info

Merus BV YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding MRUS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding MRUS

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-12-04 by SHUMAN HARRY
  • 4: filed on 2023-10-11 by LIU HUI
  • 4: filed on 2023-10-11 by SHUMAN HARRY
  • 4: filed on 2023-06-12 by KANAVY LEN
  • 4: filed on 2023-06-01 by SHUMAN HARRY
  • 4: filed on 2023-04-17 by IWICKI MARK T
  • 4: filed on 2023-04-10 by LIU HUI
  • 4: filed on 2023-02-03 by SHUMAN HARRY
  • 4: filed on 2023-02-03 by LIU HUI
  • 4: filed on 2023-02-03 by SILVERMAN PETER B.

    • Events (8k)

  • 8-K: filed on 2023-08-11:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-15:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-30:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2023-05-23:
    Item 1.02: Termination of a Material Definitive Agreement
  • 8-K: filed on 2023-04-17:
    Item 8.01: Other Events
  • 8-K: filed on 2023-01-09:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-06:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-31:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-01-25:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-08:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

  • 144: filed on 2023-06-01:
  • 144: filed on 2023-12-01:

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    575 total shares from 1 transactions

    Exercise Derivative Conversion (M)

    2.5 Thousand total shares from 1 transactions

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    SHUMAN HARRY VP CONTROLLER, PAO

    • Officer
    		 7,367 2023-12-01 5

    LIU HUI EVP, CBO & HEAD OF MERUS US

    • Officer
    		 0 2023-10-10 3

    PERRY GREGORY D CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2023-06-14 2

    GOWEN MAXINE

    • Director
    		 0 2023-06-08 1

    IWICKI MARK T

    • Director
    		 0 2023-06-08 2

    PUCCI PAOLO

    • Director
    		 0 2023-06-08 1

    MEHRA ANAND

    • Director
    		 0 2023-06-08 1

    SANDOR VICTOR

    • Director
    		 0 2023-06-08 1

    KANAVY LEN

    • Director
    		 0 2023-06-08 1

    LUNDBERG SVEN ANTE PRESIDENT, CEO & PFO

    • Officer
    • Director
    		 0 2023-02-02 1

    SILVERMAN PETER B. COO & GC

    • Officer
    		 0 2023-02-02 2

    JOE ANDREW SVP, CMO

    • Officer
    		 0 2023-02-02 1

    BAKKER LEX SVP, CHIEF DEVELOPMENT OFFICER

    • Officer
    		 55,000 2022-01-31 0

    DE KRUIF JOHN SVP & CHIEF TECHNOLOGY OFFICER

    • Officer
    		 55,000 2022-01-31 0

    GEUIJEN CECILE A W SVP & CHIEF SCIENTIFIC OFFICER

    • Officer
    		 55,000 2022-01-31 0

    BVF PARTNERS L P/IL

    BIOTECHNOLOGY VALUE FUND L P

    BVF I GP LLC

    BIOTECHNOLOGY VALUE FUND II LP

    BVF II GP LLC

    BIOTECHNOLOGY VALUE TRADING FUND OS LP

    BVF PARTNERS OS LTD.

    BVF GP HOLDINGS LLC

    BVF INC/IL

    LAMPERT MARK N

    • 10% Owner
    • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
    		7,824,899 2021-10-07 0

    INCYTE CORP

    • 10% Owner
    		 No longer subject to file 2021-01-25 0

    THROSBY MARK EVP & CHIEF SCIENTIFIC OFFICER

    • Officer
    		 45,515 2020-07-07 0

    BVF GP HOLDINGS LLC

    BVF I GP LLC

    BVF II GP LLC

    • 10% Owner
    • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
    		 3,190,994 2020-06-01 0

    SIRULNIK ANDRES EVP & CHIEF MEDICAL OFFICER

    • Officer
    		 0 2020-02-14 0

    BVF PARTNERS L P/IL

    BIOTECHNOLOGY VALUE FUND L P

    BIOTECHNOLOGY VALUE FUND II LP

    BIOTECHNOLOGY VALUE TRADING FUND OS LP

    BVF PARTNERS OS LTD.

    BVF INC/IL

    LAMPERT MARK N

    • 10% Owner
    • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
    		3,435,297 2020-01-16 0

    DE KONING JOHN

    • Director
    		 0 2020-01-01 0

    GREIG RUSSELL

    • Director
    		 0 2020-01-01 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    SHUMAN HARRY - Officer VP CONTROLLER, PAO

    		2023-12-04 16:05:15 -0500 2023-12-01 S 575 $24.58 d 7,367 direct yes 3.293 3.293 2 0.0 1

    SHUMAN HARRY - Officer VP CONTROLLER, PAO

    		2023-12-04 16:05:15 -0500 2023-12-01 M 2,500 a 7,942 direct 3.293 3.293 2 0.0 1

    SHUMAN HARRY - Officer VP CONTROLLER, PAO

    		2023-12-04 16:05:15 -0500 2023-12-01 M 2,500 d 5,000 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    MERUS NV MRUS 2023-12-08 22:15:04 UTC 4.8846 0.4354 550000
    MERUS NV MRUS 2023-12-08 21:45:04 UTC 4.8846 0.4354 550000
    MERUS NV MRUS 2023-12-08 21:15:04 UTC 4.8846 0.4354 550000
    MERUS NV MRUS 2023-12-08 20:45:04 UTC 4.8846 0.4354 550000
    MERUS NV MRUS 2023-12-08 20:15:07 UTC 4.8846 0.4354 550000
    MERUS NV MRUS 2023-12-08 19:45:04 UTC 4.8846 0.4354 550000
    MERUS NV MRUS 2023-12-08 19:15:03 UTC 4.8846 0.4354 550000
    MERUS NV MRUS 2023-12-08 18:45:03 UTC 4.8846 0.4354 550000
    MERUS NV MRUS 2023-12-08 18:15:04 UTC 4.8846 0.4354 550000
    MERUS NV MRUS 2023-12-08 17:45:03 UTC 4.8846 0.4354 550000
    MERUS NV MRUS 2023-12-08 17:15:03 UTC 4.8846 0.4354 550000
    MERUS NV MRUS 2023-12-08 16:45:05 UTC 4.8846 0.4354 550000
    MERUS NV MRUS 2023-12-08 16:15:04 UTC 4.8846 0.4354 550000
    MERUS NV MRUS 2023-12-08 15:45:04 UTC 4.8846 0.4354 550000
    MERUS NV MRUS 2023-12-08 15:15:04 UTC 4.8846 0.4354 550000
    MERUS NV MRUS 2023-12-08 14:45:04 UTC 4.8857 0.4343 550000
    MERUS NV MRUS 2023-12-08 14:15:03 UTC 4.8857 0.4343 550000
    MERUS NV MRUS 2023-12-08 13:45:03 UTC 4.892 0.428 550000
    MERUS NV MRUS 2023-12-08 13:15:04 UTC 4.892 0.428 550000
    MERUS NV MRUS 2023-12-08 12:45:05 UTC 4.892 0.428 550000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments